These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32583316)

  • 1. Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.
    Marquina C; Zomer E; Vargas-Torres S; Zoungas S; Ofori-Asenso R; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Oct; 38(10):1095-1113. PubMed ID: 32583316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
    Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
    Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults.
    Xiang Y; Gan L; Du H; Hao Q; Aertgeerts B; Li S; Hu M
    Int J Technol Assess Health Care; 2023 Aug; 39(1):e53. PubMed ID: 37650314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are PCSK9 Inhibitors Cost Effective?
    Korman MJ; Retterstøl K; Kristiansen IS; Wisløff T
    Pharmacoeconomics; 2018 Sep; 36(9):1031-1041. PubMed ID: 29777433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
    Jahangiri R; Rezapour A; Malekzadeh R; Olyaeemanesh A; Roshandel G; Motevalian SA
    PLoS One; 2022; 17(7):e0271908. PubMed ID: 35901100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.
    Suh DC; Griggs SK; Henderson ER; Lee SM; Park T
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):51-69. PubMed ID: 29148854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
    Dugré N; Lindblad AJ; Perry D; Allan GM; Braschi É; Falk J; Froentjes L; Garrison SR; Kirkwood JEM; Korownyk CS; McCormack JP; Moe SS; Paige A; Potter J; Thomas BS; Ton J; Young J; Weresch J; Kolber MR
    Can Fam Physician; 2023 Oct; 69(10):701-711. PubMed ID: 37833094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
    Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
    Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
    Kumar R; Tonkin A; Liew D; Zomer E
    Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.